We propose that in addition to other clinical factors, such as age, PSA, prostate volume, PHI and 4 K scores, the pre-biopsy serum DHEA concentration measured with LC–MS/MS may be a useful biomarker for predicting BPH or low progression risks prostate cancer. This evidence concerns the gene KLK3 and benign prostatic hyperplasia.